COVID-19 in persons with haematological cancers
- PMID: 32332856
- PMCID: PMC7180672
- DOI: 10.1038/s41375-020-0836-7
COVID-19 in persons with haematological cancers
Abstract
Infection with SARS-CoV-2, the cause of coronavirus infectious disease-19 (COVID-19), has caused a pandemic with >850,000 cases worldwide and increasing. Several studies report outcomes of COVID-19 in predominately well persons. There are also some data on COVID-19 in persons with predominately solid cancer but controversy whether these persons have the same outcomes. We conducted a cohort study at two centres in Wuhan, China, of 128 hospitalised subjects with haematological cancers, 13 (10%) of whom developed COVID-19. We also studied 226 health care providers, 16 of whom developed COVID-19 and 11 of whom were hospitalised. Co-variates were compared with the 115 subjects with haematological cancers without COVID-19 and with 11 hospitalised health care providers with COVID-19. There were no significant differences in baseline co-variates between subjects with haematological cancers developing or not developing COVID-19. Case rates for COVID-19 in hospitalised subjects with haematological cancers was 10% (95% Confidence Interval [CI], 6, 17%) compared with 7% (4, 12%; P = 0.322) in health care providers. However, the 13 subjects with haematological cancers had more severe COVID-19 and more deaths compared with hospitalised health care providers with COVID-19. Case fatality rates were 62% (32, 85%) and 0 (0, 32%; P = 0.002). Hospitalised persons with haematological cancers have a similar case rate of COVID-19 compared with normal health care providers but have more severe disease and a higher case fatality rate. Because we were unable to identify specific risk factors for COVID-19 in hospitalised persons with haematological cancers, we suggest increased surveillance and possible protective isolation.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures
Comment in
-
Reply to "COVID-19 in persons with haematological cancers": a focus on myeloid neoplasms and risk factors for mortality.Leukemia. 2020 Jul;34(7):1957-1960. doi: 10.1038/s41375-020-0877-y. Epub 2020 May 26. Leukemia. 2020. PMID: 32457356 Free PMC article. No abstract available.
-
Multiple myeloma and COVID-19.Leukemia. 2020 Jul;34(7):1961-1963. doi: 10.1038/s41375-020-0879-9. Epub 2020 Jun 1. Leukemia. 2020. PMID: 32475990 No abstract available.
-
Response to "COVID-19 in persons with haematological cancers".Leukemia. 2020 Aug;34(8):2265-2270. doi: 10.1038/s41375-020-0914-x. Epub 2020 Jun 11. Leukemia. 2020. PMID: 32528043 Free PMC article. No abstract available.
-
Clinical characteristics and outcome of SARS-CoV-2-infected patients with haematological diseases: a retrospective case study in four hospitals in Italy, Spain and the Netherlands.Leukemia. 2020 Sep;34(9):2536-2538. doi: 10.1038/s41375-020-0960-4. Epub 2020 Jul 8. Leukemia. 2020. PMID: 32641731 Free PMC article. No abstract available.
-
COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter.Leukemia. 2020 Oct;34(10):2809-2812. doi: 10.1038/s41375-020-01019-x. Epub 2020 Aug 14. Leukemia. 2020. PMID: 32801310 Free PMC article. No abstract available.
References
-
- Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020. 10.1001/jama.2020.2648. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
